Skip to main content
. 2022 Aug 21;71(8):1735–1745. doi: 10.2337/db21-1069

Figure 5.

Figure 5

Ab-2.5HIP treatment in NOD wild-type neonates enhances T-cell central tolerance and delays diabetes onset. A: 2.5HIP tetramer analysis of CD4SP thymocytes 72 h after treatment of 1-day-old NOD wild-type neonates with Ab-alone or Ab-2.5HIP (n = 5 per group). Each data point represents three to five pooled thymi enriched for 2.5HIP-reactive cells by tetramer; data represent 5 independent experiments. B: Frequency of Foxp3+ cells within tetramer-positive cells. SSC-A, side scatter area. C: Diabetes incidence of NOD wild-type female mice treated with a single 2.5-μg dose of Ab-alone or Ab-2.5HIP at 1 day old (n = 18–20 per group). D: Quantification of CD4 T cells and 2.5HIP tetramer-positive T cells in the pLN at 10 weeks after treatment. E: Quantification of Foxp3+ cells within 2.5HIP tetramer-positive T cells in the pLN at 10 weeks after treatment. F: Quantification of CD4 T cells and 2.5HIP tetramer-positive T cells in the pancreatic islets 10 weeks after treatment. G: Quantification of Foxp3+ cells within 2.5HIP tetramer-positive T cells in the pancreatic islets at 10 weeks after treatment. (D–G: n = 5–7 per group; data from two independent experiments). Data are reported as mean ± SD. Paired t test (A and B), Gehan-Breslow-Wilcoxon Test (C), and Kruskal-Wallis and Dunn test (D–G). *P < 0.05, **P < 0.01.